Interim report May-January 2019/20

Outlook maintained for the full-year – soft quarter

We delivered an improved EBITA margin supported by good sales in Neuro and Oncology Informatics as well as by our cost reduction program. However, the third quarter was disappointing from an order perspective as the U.S. business did not live up to our expectations. Our order pipeline of Elekta Unity is strong, which ensures that the order target will be met – most likely already in the fourth quarter. 

Richard Hausmann
President and CEO

Third quarter

• Gross order intake amounted to SEK 4,276 M (4,551), corresponding to an 11 percent decrease in order intake in constant currency
• Net sales were SEK 3,656 M (3,320), corresponding to a 5 percent growth in constant currency
• Gross margin amounted to 42.0 (40.7) percent
• EBITA increased by 28 percent to SEK 648 M (505), corresponding to an EBITA margin of 17.7 percent (15.2)
• Earnings per share was SEK 0.81 (0.55) before/after dilution
• Cash flow after continuous investments was SEK -224 M (-222)
• 1 Elekta Unity order booked in the quarter

Significant events after the quarter

• Québec to acquire advanced linear accelerators, at a total order value of approximately SEK 407 million
• Elekta appoints new Head of Region North and Central America

¹ After continuous investments
² Before/after dilution
³ Compared to last fiscal year based on constant currency

Outlook for fiscal year 2019/20

• Net sales growth of 8-10 percent based on constant currency
• EBITA margin of around 18 percent

# # #

For further information, please contact:
Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
Time zone: CET: Central European Time

Gustaf Salford, CFO 
Tel: +46 70 216 17 50, e-mail: gustaf.salford@elekta.com
Time zone: CET: Central European Time  

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on February 20, 2020. (REGMAR) 

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.